IP Library Granted Patent US 10,495,641
Granted Patent B2
US 10,495,641 · App. 15/897,217 · Granted Dec 3, 2019

Diagnosis and treatment of viral diseases

Inventors: Gerard Nuovo (Westerville, OH); Virginia Nivar (Marion, OH)
Assignee: Enzo Biochem, Inc.
G01N33/56994C07K16/085C07K16/244C12Q1/6883C12Q1/6886C12Q1/705C07K2317/33C07K2317/76C12N2710/16021C12Q2600/158G01N2333/03G01N2800/7052
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,495,641
App. No.
15/897,217
Granted
Dec 3, 2019
Kind
B2
Abstract

This disclosure relates to methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, Castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral disease in a patient. The disclosure further relates to methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient. In addition, the disclosure relates to methods of identifying therapeutic agents that show efficacy in reducing levels of virus-specific agents in vitro. The disclosure further relates to methods of treating idiopathic pulmonary fibrosis, a lymphoproliferative disease and cancer, as well as to methods of preventing viral infection, including Herpesvirus saimiri infection.

Claims (16)

1. A nucleic acid hybridization probe composition comprising at least one of

a locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:5, and

a locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:6.

2. The nucleic acid hybridization probe composition of claim 1 , wherein the at least one LNA oligonucleotide is labeled.

3. The nucleic acid hybridization probe composition of claim 1 , comprising both the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:5 and the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:6.

4. The nucleic acid hybridization probe composition of claim 3 , wherein both of said LNA oligonucleotides are labeled.

5. The nucleic acid hybridization probe composition of claim 3 , consisting essentially of both the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:5 and the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:6.

6. The nucleic acid hybridization probe composition of claim 5 , wherein both of said LNA oligonucleotides are labeled.

7. A nucleic acid hybridization probe composition comprising at least one of

a locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:7, and

a locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:8.

8. The nucleic acid hybridization probe composition of claim 7 , wherein the at least one LNA oligonucleotide is labeled.

9. The nucleic acid hybridization probe composition of claim 7 , comprising both the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:7 and the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:8.

10. The nucleic acid hybridization probe composition of claim 9 , wherein both of said LNA oligonucleotides are labeled.

11. The nucleic acid hybridization probe composition of claim 9 , consisting essentially of both the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:7 and the locked nucleic acid (LNA) oligonucleotide having the sequence of SEQ ID NO:8.

12. The nucleic acid hybridization probe composition of claim 11 , wherein both of said LNA oligonucleotides are labeled.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2018
From: NUOVO, GERARD; NIVAR, VIRGINIA
To: ENZO BIOCHEM, INC.
Reel/Frame 045299/0439 →
Continuity (6)
Continuation 15439495 · Feb 22, 2017
Continuation 14759687
Continuation In Part 14080644 · Nov 14, 2013
Continuation In Part 13920964 · Jun 18, 2013
Provisional Application 61750104 · Jan 8, 2013
Related Publication 20180180615A1 · Jun 28, 2018